MCO-010 Market Summary

Key Factors Driving MCO-010 Growth

1. First-in-class optogenetic therapy with mutation-agnostic design

• MCO-010 uses a multi-characteristic opsin (MCO) platform to make retinal cells light-sensitive again, enabling vision restoration.
• Works independently of genetic mutation, unlike traditional gene therapies.

2. Strong Phase IIb randomized trial efficacy (key validation driver)

• Phase IIb RESTORE trial:

o Met primary and key secondary endpoints with statistical significance

o Demonstrated clinically meaningful improvement in visual acuity in legally blind patients

o Achieved significant BCVA improvements vs sham (p≈0.02 range)

3. Durable long-term safety and efficacy (5-year data)

• 5-year follow-up (EXTEND study):

o No serious adverse events or new safety signals

o Sustained quality-of-life and vision-related improvements

• Initial trials also showed statistically significant visual acuity gains at 1 year

Growth implication:

• Long-term safety is critical for gene therapies → increases physician confidence
• Durable benefit → strong value proposition for one-time treatment

4. Late-stage regulatory momentum (near commercialization)

• Rolling Biologics License Application (BLA) submitted to FDA
• Potential positioning as first approved mutation-agnostic therapy for RP

5. High unmet need in advanced RP (target niche advantage)

• Designed for severe vision loss / late-stage RP, where:

o Photoreceptors are already lost

o No approved therapies exist

6. Simple administration and competitive positioning

• Delivered via single intravitreal injection (less invasive than subretinal surgery)

Growth implication:

• Easier adoption vs surgical gene therapies
• Potential for broader use across retinal centers

MCO-010 Recent Developments

• In March 2026, Nanoscope Therapeutics announced the publication of its latest peer-reviewed observational study in a Springer Nature journal, Documenta Ophthalmologica, advancing the field's understanding of how to measure meaningful vision improvements in patients with severe vision loss in the real world.
• In September 2025, Nanoscope Therapeutics announced that the European Medicines Agency (EMA) has granted Orphan designations to MCO-010 (sonpiretigene isteparvovec) across five categories of retinal dystrophies. In addition, the US Food and Drug Administration (FDA) has granted RMAT designation for MCO-010 in Stargardt disease (SD).

“MCO-010 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of MCO-010 for potential indication like Retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis in the 7MM. A detailed picture of MCO-010’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the MCO-010 for potential indications. The MCO-010 market report provides insights about MCO-010’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current MCO-010 performance, future market assessments inclusive of the MCO-010 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of MCO-010 sales forecasts, along with factors driving its market.

MCO-010 Drug Summary

MCO-010 is an investigational, mutation-agnostic optogenetic therapy developed by Nanoscope Therapeutics for the treatment of advanced retinitis pigmentosa. It utilizes an adeno-associated virus (AAV) vector to deliver a gene encoding a proprietary multi-characteristic opsin (MCO) to retinal bipolar cells, enabling these cells to become light-sensitive and restore visual signaling in the absence of functional photoreceptors. Administered as a one-time intravitreal injection, MCO-010 is designed to bypass damaged photoreceptors and directly stimulate downstream retinal pathways, offering potential vision restoration regardless of the underlying genetic mutation. Early clinical studies have demonstrated improvements in visual acuity and functional vision in patients with severe vision loss, supporting its development as a novel, less invasive optogenetic therapy compared to approaches requiring external light-stimulating devices. The report provides MCO-010’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the MCO-010 Market Report

The report provides insights into:

• A comprehensive product overview including the MCO-010 MoA, description, dosage and administration, research and development activities in potential indication like Retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis.
• Elaborated details on MCO-010 regulatory milestones and other development activities have been provided in MCO-010 market report.
• The report also highlights MCO-010‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The MCO-010 market report also covers the patents information, generic entry and impact on cost cut.
• The MCO-010 market report contains current and forecasted MCO-010 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The MCO-010 market report also features the SWOT analysis with analyst views for MCO-010 in potential indications.

Methodology

The MCO-010 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MCO-010 Analytical Perspective by DelveInsight

• In-depth MCO-010 Market Assessment

This MCO-010 sales market forecast report provides a detailed market assessment of MCO-010 for potential indication like Retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted MCO-010 sales data uptil 2034.

• MCO-010 Clinical Assessment

The MCO-010 market report provides the clinical trials information of MCO-010 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

MCO-010 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

MCO-010 Market Potential & Revenue Forecast

• Projected market size for the MCO-010 and its key indications
• Estimated MCO-010 sales potential (MCO-010 peak sales forecasts)
• MCO-010 Pricing strategies and reimbursement landscape

MCO-010 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• MCO-010 Market positioning compared to existing treatments
• MCO-010 Strengths & weaknesses relative to competitors

MCO-010 Regulatory & Commercial Milestones

• MCO-010 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

MCO-010 Clinical Differentiation

• MCO-010 Efficacy & safety advantages over existing drugs
• MCO-010 Unique selling points

MCO-010 Market Report Highlights

• In the coming years, the MCO-010 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The MCO-010 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MCO-010’s dominance.
• Other emerging products for Retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis are expected to give tough market competition to MCO-010 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MCO-010 in potential indications.
• Analyse MCO-010 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted MCO-010 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of MCO-010 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of MCO-010? How strong is MCO-010’s clinical and commercial performance?
• What is MCO-010’s clinical trial status in each individual indications such as Retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MCO-010 Manufacturers?
• What are the key designations that have been granted to MCO-010 for potential indications? How are they going to impact MCO-010’s penetration in various geographies?
• What is the current and forecasted MCO-010 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of MCO-010 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to MCO-010 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is MCO-010? What is the duration of therapy and what are the geographical variations in cost per patient?